FVR - Finnish Vaccine Research Ltd.
Kirsi Komi is a seasoned board member and chair with extensive experience in various organizations. Currently serving as a Member of the Board at FVR - Suomen rokotetutkimus since May 2023, Kirsi Komi also holds the position of Chair at Virta Ltd and has been Chair of Docrates Syöpäsairaala - Docrates Cancer Center since 2011, with tenure continuing through September 2024. Previous leadership roles include Chair of the Nomination Committee at Directors' Institute Finland and Vice Chair, as well as membership on several boards, including Humana AB, Metsä Board, and Finnvera Oyj, where Kirsi Komi also served as Chair of the Audit Committee. Kirsi Komi's educational background includes a Master of Laws (LL.M.) from the University of Helsinki.
This person is not in any teams
FVR - Finnish Vaccine Research Ltd.
Vaccines improve the quality of life by preventing serious illnesses. They play a key role in promoting public health. At FVR – Finnish Vaccine Research, we study the quality, safety and efficacy of vaccines with decades of experience and internationally recognized, high-quality scientific expertise. FVR - Finnish Vaccine research is a special-assignment company of the state, which builds on the solid foundation of vaccine research expertise of the Tampere University’s Vaccine Research Center and the Finnish Institute for Health and Welfare’s (THL) vaccine research, combining the two.